

**Corporate Office:** 

1<sup>st</sup> Floor, Premdeep Building, Above Latur Urban Co-Op. Bank Ltd., Lulla Nagar Chowk, Camp-Kondhwa Road, Pune - 411 040. (Maharashtra) INDIA. Tel.: +91-20-41471234 Émail: enquiry@cian.co, cianhealthcare@yahoo.co.in Web: www.cian.co

## **Registered Office:**

Milkant No. 3339, Block No.1 from South Side, C.S. No. 227/2+3A, Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308, (Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

Factory: Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar, Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: U24233PN2003PLC017563

Date: 12<sup>th</sup> November, 2019

To, **BSE Limited – CRD** P.J. Towers, Dalal Street. Fort, Mumbai-400001

## Script Code: 542678

## Sub: SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2019 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015.

Dear Sir(s),

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Unaudited Financials Results for the Half year ended 30<sup>th</sup> September, 2019 in the form of PDF which was also approved by the Audit Committee and the Board of Directors of the Company at their meeting held on Tuesday, 12th November, 2019.

We are in process to file the aforesaid financial results in the form of XBRL within the stipulated time of 24 hours from the conclusion of the board meeting and the same shall also be hosted at the website of the Company.

You are requested to take on record the Unaudited Financial Results along with Limited Review Report for your reference and record.

ALTH

PUNE

Thanking You,

Yours Faithfully,

For Cian Healthcare Limited

Suraj Shriniwas Zanwar **Managing** Director DIN: 01304850

Encls: Unaudited Financial Results and Limited Review Report.

Add: MILKAT NO.3339,BLOCK NO HARPALE PARK,OPP.BERGER P		IDE,C.S.NO. 227/2+3. PUNE MH 412308 IN		
Statement of Profit and Loss for t				
l i i i i i i i i i i i i i i i i i i i		Half Van Ended		(`in Lakhs)
		Half Year Ended	Corresponding 6	Year Ended
Particulars	September 30th 2019	Preceding 6 months ended on March 31st, 2019	months ended in previous year on September 30th, 2018	March 31st 2019
	Unaudited	Audited	Audited*	Audited
Revenue from Operations	2,941.30	2,970.71	3,273.47	6,244.17
Other Operating Revenue	(0.01)	(0.59)		(0.59)
Other Income	12.58	68.03	27.99	96.03
Total Income	2,953.88	3,038.15	3,301.46	6,339.61
EXPENSES				
Cost of Material Consumed	1,968.30	2,105.21	1,937.03	4,042.24
Operating Expenses	249.05	476.01		476.01
Employee Benefit expenses	249.35	228.93	333.65	562.57
Administrative Expenses	152.25	179.87	179.38	359.25
Finance Cost	292.71	273.57	236.05	509.62
Depreciation and amortization expenses	160.77	179.70	112.55	292.25
* Total Expenses	3,072.43	3,443.30	2,798.65	6,241.95
Profit/(Loss) before exceptional items and tax	(118.56)	(405.15)	502.81	97.66
Exceptional Items		-3.58		(3.58)
Profit/(Loss) before tax	(118.56)	(408.74)	502.81	94.08
Tax expenses				
(1) Current tax		(118.59)	135.17	16.57
Mat credit entitlement (2) Deferred tax		11.98		11.98
Tax reversal of earlier year				
Profit (Loss) for the period from continuing operations	(118.56)	(302.12)	367.65	65,52
Profit(Loss) from discontinued operations				•
Tax expenses of discontinued operations				
Profit(Loss) from discontinued operations (after tax)	-		-	-
Profit/loss for the period	(118.56)	(302.12)	367.65	65.52
Other Comprehensive Income Items that will not be reclassified to profit				
or loss :				
Re-measurement gains/ (losses) on defined benefit plans	-	Martin States		
Income tax effect				-
Items that will be reclassified to profit or loss	-		C. S. S. S. S.	-
Income tax relating to items that will be reclassified to profit or loss	-			
Total other Comprehensive Income for the Year, net of tax	-			
Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(118.56)	(302.12)	367.65	65.52
Earning per equity share (For continuing operations ):				
i) Basic ( per share) ii) Diluted ( per share)	(0.51) (0.51)	(1.76) (1.76)	2.19 2.19	0.38 0.38
Earning per equity share (For discontinued operations): i) Basic (`per share) ii) Diluted (`per share)	:			:
Earning per equity share (For discontinued & continuing operations): i) Basic (* per share) ii) Diluted (* per share)				

Notes:

Notes: 1) The above results were reviewed by an Audit Committee and thereafter taken on record by the Board of Directors in their Meeting on 12/11/2019 2) There were no investor complaints known to the Company outstanding at the beginning of half year 3) Previous period figures have been regrouped whenever necessary 4) As the company was planning to go for IPO, the company's Financials for the half year ended on 30th September, 2018 were audited by M/s. Hanumantrao Lad & Associates, Chartered Accountants, Pune. 5) Considering the nature of Company's business, there is only one reportable segment in accordance with the requirement of IND AS-108 on "Segment Reporting", have a concarted disclowing of the company for the company one reportable segment in accordance with the requirement of IND AS-108 on "Segment Reporting",

hence separate disclosure of the segment information is not considered necessary. 6) The Financial results for the half year and Year ended on 30th September 2019, are available on the website of the company (www.cian.co) and website of the

Stock Exchange (www.bseindia.com) 7) The above Financial results have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014

JD

Se 140

.

For and on behalf of Bo	oard of Directors	HEALTH CA
<b>Suraj Zanwar</b> Director DIN: 01304850	K	cian
Place: Pune	21	

PUNE

ALTH CAP

Statement of Assets and Liabilities as Particulars ent assets Plant and Equipment ork-in- progress held for sale ingible Assets Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) n Current Assets assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets r Financial Assets tx assets (net) rent assets	As at September 30th ,2019 As at September 30th 2019 2,183.25 2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15 136.56	( in Lakhs) As at 31st March 2019 2,347.65 637.11 (222.52 1,594.92 2,061.31 99.67
ent assets Plant and Equipment ork-in- progress held for sale ingible Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) n Current Assets assets assets Receivables and Cash equivalents r Financial assets-FD with Banks r Financial Assets ix assets (net)	2,183.25 2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15	As at 31st March 2019 2,347.65 637.11 (222.52 1,594.92 2,061.31
ent assets Plant and Equipment ork-in- progress held for sale ingible Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) n Current Assets assets assets Receivables and Cash equivalents r Financial assets-FD with Banks r Financial Assets ix assets (net)	2,183.25 2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15	2,347.65 637.11 - (222.52 1,594.92 2,061.31
Plant and Equipment ork-in- progress held for sale ingible Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) in Current Assets assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets r Financial Assets assets (net)	2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15	637.11 (222.52 1,594.92 2,061.31
Plant and Equipment ork-in- progress held for sale ingible Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) in Current Assets assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets r Financial Assets assets (net)	2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15	637.11 (222.52 1,594.92 2,061.31
ork-in- progress held for sale ingible Assets Assets hent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) in Current Assets assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets r Financial Assets ix assets (net)	2,260.05 511.68 1,027.46 1,643.19 2,351.71 158.15	637.11 - (222.52 1,594.92 2,061.31
neld for sale angible Assets Assets ment in Shares of Dr. Smiths Biotech Private Limited tax assets (net) a Current Assets assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets to assets (net)	511.68 1,027.46 1,643.19 2,351.71 158.15	- (222.52 1,594.92 2,061.31
ngible Assets Assets nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) a Current Assets assets assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets r Financial Assets tax assets (net)	1,027.46 1,643.19 2,351.71 158.15	1,594.92 2,061.31
nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) a Current Assets assets es Assets Receivables and Cash equivalents r Financial assets-FD with Banks r Financial assets r Financial Assets assets (net)	1,027.46 1,643.19 2,351.71 158.15	1,594.92 2,061.31
nent in Shares of Dr. Smiths Biotech Private Limited tax assets (net) a Current Assets assets es Assets Receivables and Cash equivalents r Financial assets-FD with Banks r Financial assets r Financial Assets assets (net)	1,027.46 1,643.19 2,351.71 158.15	1,594.92 2,061.31
tax assets (net) a Current Assets assets assets Assets Receivables and Cash equivalents r Financial assets-FD with Banks r Financial assets r Financial Assets tassets (net)	1,643.19 2,351.71 158.15	1,594.92 2,061.3
assets es Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets assets (net)	1,643.19 2,351.71 158.15	1,594.92 2,061.3
Assets Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets ax assets (net)	2,351.71 158.15	2,061.3
Assets Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets ax assets (net)	2,351.71 158.15	2,061.31
Receivables and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets ax assets (net)	158.15	
and Cash equivalents Financial assets-FD with Banks Financial assets Financial Assets ax assets (net)	158.15	
Financial assets-FD with Banks Financial assets Financial Assets ax assets (net)		99.0
Financial assets Financial Assets ax assets (net)	150.50	133.40
r Financial Assets ax assets (net)		135.40
	250.66	197.94
rent assets	-	
	1,341.44	1,159.99
Total Assets	11,864.15	8,009.48
AND LIABILITIES		
AND LIADILITIES		
are capital	2,336.08	1,714.43
uity	3,507.37	455.7
ent liabilities		
Liabilities		
vings	2,526.68	2,286.4
financial liabilities		
S	51.73	51.7
	135.35	135.3
n-current liabilities		
liabilities		
	2,749.02	2,579.2
	232.61	559.1
		07.5
financial habilities	97.55	97.5
rent liabilities	63.80	89.5
S	37.09	40.1
Total Equity and Liabilities	11,864.15	8,009.4
	AND LIABILITIES hare capital uity rent liabilities Liabilities vings financial liabilities s tax liabilities (net) n-current liabilities liabilities Liabilities Liabilities wings de payables-MSME de payables-Others financial liabilities rent liabilities rent liabilities s Total Equity and Liabilities on behalf of Board of Directors unwar 04850	hare capital hity 2,336.08 3,507.37 rent liabilities Liabilities s 2,526.68 financial liabilities s 51.73 tax liabilities Liabilities Liabilities Liabilities Liabilities Liabilities Liabilities S 2,749.02 de payables-MSME de payables-MSME 232.61 126.87 financial liabilities S 37.09 Total Equity and Liabilities S 37.09



## Agarwal Mahesh K. & Co.

Chartered Accountants

 19, 5th Floor, Hansmani Society, Nr. Dandekar Bridge, Navi Peth, Pune - 411 030.
 agarwalmaheshkca@gmail.com

: agarwalmanesinca@gman.com
 : www.agarwalmahesh.com

□ : +91 9028109491, 9766909029, 7758883321

Independent Auditor's Review Report on unaudited half yearly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors Cian Healthcare Limited Pune

We have reviewed the accompanying statement of unaudited standalone financial results of Cian Healthcare Limited ('the Company') for the Half year ended September 30, 2019 and for the year-to-date results for the period from April 1, 2019 to September 30, 2019 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').

This statement is the responsibility of the Company's Management and has been approved by the Board of directors And statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agarwal Mahesh K & Co. Chartered Accountants Anesh FRN: 008007C CA Ashish Boundia Partner Membership No. 156089 UDIN No.:- 19156089AAAAAU6963 Place: - Pune, Date: - 12.11.2019